Denali Therapeutics Inc.
DNLI
$14.80
$0.432.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -84.83% | 1.58% | |||
| Gross Profit | 84.83% | -1.58% | |||
| SG&A Expenses | -2.35% | 20.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.12% | 5.41% | |||
| Operating Income | -12.12% | -5.41% | |||
| Income Before Tax | -15.94% | -6.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.87% | -7.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.87% | -7.05% | |||
| EBIT | -12.12% | -5.41% | |||
| EBITDA | -10.56% | -7.16% | |||
| EPS Basic | -15.10% | -6.66% | |||
| Normalized Basic EPS | -12.50% | -12.32% | |||
| EPS Diluted | -15.10% | -6.66% | |||
| Normalized Diluted EPS | -12.50% | -12.32% | |||
| Average Basic Shares Outstanding | 0.67% | 0.37% | |||
| Average Diluted Shares Outstanding | 0.67% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||